Drug Information

Drug General Information
Drug ID
D0M8OC
Former ID
DNCL003065
Drug Name
Bavisant
Synonyms
JNJ-31001074
Drug Type
Small molecular drug
Indication Attention deficit hyperactivity disorder [ICD9: 314; ICD10:F90] Phase 2 [522173]
Company
Johnson & Johnson Pharmaceutical Research & Development
Structure
Download
2D MOL

3D MOL
Formula
C19H27N3O2
Canonical SMILES
C1CC1N2CCN(CC2)C(=O)C3=CC=C(C=C3)CN4CCOCC4
InChI
1S/C19H27N3O2/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20/h1-4,18H,5-15H2
InChIKey
BGBVSGSIXIIREO-UHFFFAOYSA-N
PubChem Compound ID
16061509
PubChem Substance ID
24702663, 26597871, 29946032, 135267719, 135626625, 140587789, 160676383, 172918190, 186014850, 198953087, 202535645, 210275150, 210280789, 224086232, 226834751, 243839799
Target and Pathway
Target(s) Histamine H3 receptor Target Info Antagonist [531879]
KEGG Pathway Neuroactive ligand-receptor interaction
Reactome Histamine receptors
G alpha (i) signalling events
WikiPathways Monoamine Transport
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 522173ClinicalTrials.gov (NCT00566449) A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.. U.S. National Institutes of Health.
Ref 531879Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.